{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:43:49Z","timestamp":1788799429352,"version":"build-2803163510"},"reference-count":102,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ccm.2023.06.009","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T16:12:30Z","timestamp":1692029550000},"page":"771-783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Treatment of Mycobacterium avium Complex Pulmonary Disease: When Should I Treat and What Therapy Should I Start?"],"prefix":"10.1016","volume":"44","author":[{"given":"Minh-Vu H.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Daley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ccm.2023.06.009_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.ccm.2023.06.009_bib2","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1183\/09031936.00149212","article-title":"The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study","volume":"42","author":"Hoefsloot","year":"2013","journal-title":"Eur Respir J"},{"issue":"Pt 9","key":"10.1016\/j.ccm.2023.06.009_bib3","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1099\/ijs.0.64190-0","article-title":"Mycobacterium colombiense sp. nov., a novel member of the Mycobacterium avium complex and description of MAC-X as a new ITS genetic variant","volume":"56","author":"Murcia","year":"2006","journal-title":"Int J Syst Evol Microbiol"},{"issue":"Pt 10","key":"10.1016\/j.ccm.2023.06.009_bib4","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1099\/ijs.0.65503-0","article-title":"Mycobacterium arosiense sp. nov., a slowly growing, scotochromogenic species causing osteomyelitis in an immunocompromised child","volume":"58","author":"Bang","year":"2008","journal-title":"Int J Syst Evol Microbiol"},{"issue":"Pt 11","key":"10.1016\/j.ccm.2023.06.009_bib5","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1099\/ijs.0.010637-0","article-title":"Mycobacterium marseillense sp. nov., Mycobacterium timonense sp. nov. and Mycobacterium bouchedurhonense sp. nov., members of the Mycobacterium avium complex","volume":"59","author":"Ben Salah","year":"2009","journal-title":"Int J Syst Evol Microbiol"},{"issue":"Pt 9","key":"10.1016\/j.ccm.2023.06.009_bib6","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1099\/ijs.0.008854-0","article-title":"Proposal to elevate Mycobacterium avium complex ITS sequevar MAC-Q to Mycobacterium vulneris sp. nov","volume":"59","author":"van Ingen","year":"2009","journal-title":"Int J Syst Evol Microbiol"},{"issue":"Pt 1","key":"10.1016\/j.ccm.2023.06.009_bib7","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1099\/ijs.0.037465-0","article-title":"Mycobacterium yongonense sp. nov., a slow-growing non-chromogenic species closely related to Mycobacterium intracellulare","volume":"63","author":"Kim","year":"2013","journal-title":"Int J Syst Evol Microbiol"},{"issue":"8","key":"10.1016\/j.ccm.2023.06.009_bib8","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1099\/ijsem.0.001158","article-title":"Mycobacterium paraintracellulare sp. nov., for the genotype INT-1 of Mycobacterium intracellulare","volume":"66","author":"Lee","year":"2016","journal-title":"Int J Syst Evol Microbiol"},{"issue":"11","key":"10.1016\/j.ccm.2023.06.009_bib9","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1099\/ijsem.0.003026","article-title":"A\u00a0definition of the Mycobacterium avium complex for taxonomical and clinical purposes, a review","volume":"68","author":"van Ingen","year":"2018","journal-title":"Int J Syst Evol Microbiol"},{"issue":"6","key":"10.1016\/j.ccm.2023.06.009_bib10","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1378\/chest.12-0494","article-title":"Clinical significance of the differentiation between Mycobacterium avium and Mycobacterium intracellulare in M. avium complex lung disease","volume":"142","author":"Koh","year":"2012","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.ccm.2023.06.009_bib11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.diagmicrobio.2017.02.017","article-title":"Distribution and clinical significance of Mycobacterium avium complex species isolated from respiratory specimens","volume":"88","author":"Kim","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ccm.2023.06.009_bib12","volume":"vol. M24","year":"2018"},{"key":"10.1016\/j.ccm.2023.06.009_bib13","volume":"vol. M62","year":"2018"},{"issue":"4","key":"10.1016\/j.ccm.2023.06.009_bib14","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.chest.2018.01.024","article-title":"Microbiologic outcome of interventions against Mycobacterium avium complex pulmonary disease: a systematic review","volume":"153","author":"Diel","year":"2018","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.ccm.2023.06.009_bib15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/14787210.2020.1720650","article-title":"Antibiotic therapy success rate in pulmonary Mycobacterium avium complex: a systematic review and meta-analysis","volume":"18","author":"Nasiri","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"suppl_2","key":"10.1016\/j.ccm.2023.06.009_bib16","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/jac\/dkx311","article-title":"Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex disease","volume":"72","author":"Pasipanodya","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.ccm.2023.06.009_bib17","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/cid\/cix517","article-title":"Treatment outcomes of Mycobacterium avium complex lung disease: a systematic review and meta-analysis","volume":"65","author":"Kwak","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.ccm.2023.06.009_bib18","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1164\/ajrccm.149.5.8173775","article-title":"Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease","volume":"149","author":"Wallace","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.ccm.2023.06.009_bib19","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1378\/chest.107.4.1035","article-title":"Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France","volume":"107","author":"Dautzenberg","year":"1995","journal-title":"Chest"},{"issue":"6 Pt 1","key":"10.1016\/j.ccm.2023.06.009_bib20","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1164\/ajrccm.153.6.8665032","article-title":"Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients","volume":"153","author":"Wallace","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.ccm.2023.06.009_bib21","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1164\/ajrccm.160.3.9811086","article-title":"Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease","volume":"160","author":"Tanaka","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.ccm.2023.06.009_bib22","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/clinids\/23.5.983","article-title":"Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus","volume":"23","author":"Griffith","year":"1996","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.ccm.2023.06.009_bib23","first-page":"761","article-title":"Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline)","volume":"95","author":"Zuckerman","year":"2011","journal-title":"Med Clin"},{"issue":"12","key":"10.1016\/j.ccm.2023.06.009_bib24","doi-asserted-by":"crossref","first-page":"905","DOI":"10.7326\/0003-4819-121-12-199412150-00001","article-title":"Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team","volume":"121","author":"Chaisson","year":"1994","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.ccm.2023.06.009_bib25","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1086\/514748","article-title":"A\u00a0randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex","volume":"28","author":"Gordin","year":"1999","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.ccm.2023.06.009_bib26","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1086\/320512","article-title":"Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease","volume":"32","author":"Griffith","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.ccm.2023.06.009_bib27","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1164\/rccm.201206-1088OC","article-title":"Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease","volume":"186","author":"Koh","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2023.06.009_bib28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.rmed.2006.04.002","article-title":"A\u00a0double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease","volume":"101","author":"Kobashi","year":"2007","journal-title":"Respir Med"},{"issue":"11","key":"10.1016\/j.ccm.2023.06.009_bib29","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1086\/420742","article-title":"Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases","volume":"38","author":"Peloquin","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.ccm.2023.06.009_bib30","doi-asserted-by":"crossref","first-page":"e004143","DOI":"10.1136\/bmjopen-2013-004143","article-title":"Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies","volume":"4","author":"Hwang","year":"2014","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.ccm.2023.06.009_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02052-16","article-title":"Clofazimine-containing regimen for the treatment of Mycobacterium abscessus lung disease","volume":"61","author":"Yang","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.ccm.2023.06.009_bib32","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.chest.2017.04.175","article-title":"Safety and effectiveness of clofazimine for primary and refractory nontuberculous mycobacterial infection","volume":"152","author":"Martiniano","year":"2017","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.ccm.2023.06.009_bib33","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1128\/AAC.01505-12","article-title":"In\u00a0vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease","volume":"56","author":"van Ingen","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.ccm.2023.06.009_bib34","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1378\/chest.15-0543","article-title":"Long-term follow-up of Mycobacterium avium complex lung disease in patients treated with regimens Including clofazimine and\/or rifampin","volume":"149","author":"Jarand","year":"2016","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.ccm.2023.06.009_bib35","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02308-2016","article-title":"World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update","volume":"49","author":"Falzon","year":"2017","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.ccm.2023.06.009_bib36","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1164\/rccm.200603-450OC","article-title":"Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease","volume":"174","author":"Griffith","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.ccm.2023.06.009_bib37","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1128\/AAC.02281-12","article-title":"Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen","volume":"57","author":"Koh","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.ccm.2023.06.009_bib38","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01798-16","article-title":"In\u00a0vitro susceptibility testing of bedaquiline against Mycobacterium avium complex","volume":"61","author":"Brown-Elliott","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.ccm.2023.06.009_bib39","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00665-19","article-title":"In\u00a0vitro activity of bedaquiline and delamanid against nontuberculous mycobacteria, including macrolide-resistant clinical isolates","volume":"63","author":"Kim","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.ccm.2023.06.009_bib40","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1378\/chest.14-2764","article-title":"Preliminary results of bedaquiline as salvage therapy for patients with nontuberculous mycobacterial lung disease","volume":"148","author":"Philley","year":"2015","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.ccm.2023.06.009_bib41","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1093\/jac\/dku504","article-title":"Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug","volume":"70","author":"Svensson","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.ccm.2023.06.009_bib42","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1128\/AAC.47.5.1736-1738.2003","article-title":"In\u00a0vitro activity of linezolid against slowly growing nontuberculous Mycobacteria","volume":"47","author":"Brown-Elliott","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.ccm.2023.06.009_bib43","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1183\/09031936.00169114","article-title":"The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease","volume":"45","author":"Winthrop","year":"2015","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.ccm.2023.06.009_bib44","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1128\/JCM.00274-17","article-title":"In\u00a0vitro susceptibility testing of tedizolid against nontuberculous mycobacteria","volume":"55","author":"Brown-Elliott","year":"2017","journal-title":"J\u00a0Clin Microbiol"},{"issue":"1","key":"10.1016\/j.ccm.2023.06.009_bib45","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1513\/AnnalsATS.201308-266OC","article-title":"Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study","volume":"11","author":"Miwa","year":"2014","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.ccm.2023.06.009_bib46","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jiac.2021.10.003","article-title":"Impact of rifampicin on the pharmacokinetics of clarithromycin and 14-hydroxy clarithromycin in patients with multidrug combination therapy for pulmonary Mycobacterium avium complex infection","volume":"28","author":"Iketani","year":"2022","journal-title":"J\u00a0Infect Chemother"},{"issue":"1","key":"10.1016\/j.ccm.2023.06.009_bib47","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1164\/rccm.201408-1545OC","article-title":"Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease","volume":"191","author":"Jeong","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.ccm.2023.06.009_bib48","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1378\/chest.13-2538","article-title":"Macrolide\/azalide therapy for nodular\/bronchiectatic Mycobacterium avium complex lung disease","volume":"146","author":"Wallace","year":"2014","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.ccm.2023.06.009_bib49","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1086\/515597","article-title":"Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients","volume":"178","author":"Griffith","year":"1998","journal-title":"J\u00a0Infect Dis"},{"issue":"8","key":"10.1016\/j.ccm.2023.06.009_bib50","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.1128\/AAC.00648-15","article-title":"Response to switch from intermittent therapy to daily therapy for refractory nodular bronchiectatic Mycobacterium avium complex lung disease","volume":"59","author":"Koh","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.ccm.2023.06.009_bib51","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1164\/rccm.200509-1531OC","article-title":"Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease","volume":"173","author":"Lam","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2023.06.009_bib52","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.thorsurg.2018.09.011","article-title":"Surgical treatment of pulmonary nontuberculous mycobacterial infections","volume":"29","author":"Mitchell","year":"2019","journal-title":"Thorac Surg Clin"},{"issue":"3","key":"10.1016\/j.ccm.2023.06.009_bib53","first-page":"671","article-title":"Lady Windermere revisited: treatment with thoracoscopic lobectomy\/segmentectomy for right middle lobe and lingular bronchiectasis associated with non-tuberculous mycobacterial disease","volume":"40","author":"Yu","year":"2011","journal-title":"Eur J Cardio Thorac Surg"},{"issue":"2","key":"10.1016\/j.ccm.2023.06.009_bib54","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01812-17","article-title":"Intermittent antibiotic therapy for recurrent nodular bronchiectatic Mycobacterium avium complex lung disease","volume":"62","author":"Jhun","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.ccm.2023.06.009_bib55","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jiac.2018.07.021","article-title":"Efficacy and safety of intermittent maintenance therapy after successful treatment of Mycobacterium avium complex lung disease","volume":"25","author":"Asakura","year":"2019","journal-title":"J\u00a0Infect Chemother"},{"issue":"1","key":"10.1016\/j.ccm.2023.06.009_bib56","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12890-019-0982-8","article-title":"Role of ethambutol and rifampicin in the treatment of Mycobacterium avium complex pulmonary disease","volume":"19","author":"Kim","year":"2019","journal-title":"BMC Pulm Med"},{"issue":"9","key":"10.1016\/j.ccm.2023.06.009_bib57","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.3346\/jkms.2020.35.e59","article-title":"Treatment outcomes after discontinuation of ethambutol due to adverse events in Mycobacterium avium complex lung disease","volume":"35","author":"Kwon","year":"2020","journal-title":"J\u00a0Kor Med Sci"},{"issue":"11","key":"10.1016\/j.ccm.2023.06.009_bib58","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1164\/rccm.201501-0067OC","article-title":"Comparison of clinical features, virulence, and relapse among Mycobacterium avium complex species","volume":"191","author":"Boyle","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.ccm.2023.06.009_bib59","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02503-2016","article-title":"Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype","volume":"50","author":"Koh","year":"2017","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.ccm.2023.06.009_bib60","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1513\/AnnalsATS.201605-344BC","article-title":"Relapse versus reinfection of Mycobacterium avium complex pulmonary disease. Patient characteristics and macrolide susceptibility","volume":"13","author":"Boyle","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"10.1016\/j.ccm.2023.06.009_bib61","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1164\/rccm.200905-0778OC","article-title":"Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors","volume":"181","author":"Andrejak","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.ccm.2023.06.009_bib62","doi-asserted-by":"crossref","first-page":"e008058","DOI":"10.1136\/bmjopen-2015-008058","article-title":"Retrospective study of the predictors of mortality and radiographic deterioration in 782 patients with nodular\/bronchiectatic Mycobacterium avium complex lung disease","volume":"5","author":"Gochi","year":"2015","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.ccm.2023.06.009_bib63","doi-asserted-by":"crossref","first-page":"582","DOI":"10.5588\/ijtld.15.0807","article-title":"Mortality among patients with pulmonary non-tuberculous mycobacteria disease","volume":"20","author":"Fleshner","year":"2016","journal-title":"Int J Tubercul Lung Dis"},{"issue":"11","key":"10.1016\/j.ccm.2023.06.009_bib64","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1513\/AnnalsATS.201604-246OC","article-title":"Macrolide-resistant Mycobacterium avium complex lung disease: analysis of 102 consecutive cases","volume":"13","author":"Morimoto","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"11","key":"10.1016\/j.ccm.2023.06.009_bib65","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1128\/AAC.01240-16","article-title":"Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant Mycobacterium avium complex lung disease","volume":"60","author":"Moon","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.ccm.2023.06.009_bib66","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00170-2018","article-title":"Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement","volume":"51","author":"van Ingen","year":"2018","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.ccm.2023.06.009_bib67","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1164\/rccm.201503-0444OC","article-title":"Semiquantitative culture analysis during therapy for Mycobacterium avium complex lung disease","volume":"192","author":"Griffith","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.ccm.2023.06.009_bib68","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01636-2018","article-title":"Unresolved issues in treatment outcome definitions for nontuberculous mycobacterial pulmonary disease","volume":"53","author":"Moon","year":"2019","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ccm.2023.06.009_bib69","doi-asserted-by":"crossref","first-page":"e0152221","DOI":"10.1128\/aac.01522-21","article-title":"Efficacy of fluoroquinolones as substitutes for ethambutol or rifampin in the treatment of Mycobacterium avium complex pulmonary disease according to radiologic types","volume":"66","author":"Lee","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.ccm.2023.06.009_bib70","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.201604-0700OC","article-title":"Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease","volume":"195","author":"Olivier","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.ccm.2023.06.009_bib71","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study","volume":"198","author":"Griffith","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.ccm.2023.06.009_bib72","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jac\/dkh523","article-title":"Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum","volume":"55","author":"Nash","year":"2005","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.ccm.2023.06.009_bib73","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s12931-019-1258-9","article-title":"Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium avium complex pulmonary disease: a systematic review and meta-analysis","volume":"20","author":"Park","year":"2019","journal-title":"Respir Res"},{"issue":"Suppl 2","key":"10.1016\/j.ccm.2023.06.009_bib74","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-210927","article-title":"British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)","volume":"72","author":"Haworth","year":"2017","journal-title":"Thorax"},{"key":"10.1016\/j.ccm.2023.06.009_bib75","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12879-016-1384-7","article-title":"Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease","volume":"16","author":"Kadota","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"7","key":"10.1016\/j.ccm.2023.06.009_bib76","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jiac.2020.02.008","article-title":"Effective treatment for clarithromycin-resistant Mycobacterium avium complex lung disease","volume":"26","author":"Adachi","year":"2020","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.ccm.2023.06.009_bib77","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.rmed.2017.08.031","article-title":"Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort","volume":"131","author":"Zweijpfenning","year":"2017","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.ccm.2023.06.009_bib78","doi-asserted-by":"crossref","first-page":"e256","DOI":"10.1093\/cid\/ciaa1361","article-title":"Management of drug toxicity in Mycobacterium avium complex pulmonary disease: an expert panel survey","volume":"73","author":"van Ingen","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.ccm.2023.06.009_bib79","doi-asserted-by":"crossref","first-page":"ofaa079","DOI":"10.1093\/ofid\/ofaa079","article-title":"Clinical management of respiratory adverse events associated with amikacin liposome inhalation suspension: results from a patient survey","volume":"7","author":"Swenson","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"10.1016\/j.ccm.2023.06.009_bib80","doi-asserted-by":"crossref","first-page":"e0115621","DOI":"10.1128\/AAC.01156-21","article-title":"Epetraborole is active against Mycobacterium abscessus","volume":"65","author":"Ganapathy","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ccm.2023.06.009_bib81","first-page":"S659","article-title":"In\u00a0vitro activities of epetraborole, a novel bacterial leucyl-tRNA synthetase inhibitor, against Mycobacterium avium complex isolates","volume":"9","author":"De Stefano","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ccm.2023.06.009_bib82","doi-asserted-by":"crossref","first-page":"S655","DOI":"10.1093\/ofid\/ofac492.1334","article-title":"Epetraborole, a novel bacterial leucyl-tRNA synthetase inhibitor, demonstrates potent efficacy and improves efficacy of a standard of care regimen against Mycobacterium avium complex in a chronic mouse lung infection model","volume":"9","author":"De","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ccm.2023.06.009_bib83","doi-asserted-by":"crossref","first-page":"S652","DOI":"10.1093\/ofid\/ofac492.1327","article-title":"Dose-response studies of the novel bacterial leucyl-tRNA synthetase inhibitor, epetraborole, in the intracellular hollow fiber system model of Mycobacterium avium complex lung disease","volume":"9","author":"Chapagain","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ccm.2023.06.009_bib84","doi-asserted-by":"crossref","first-page":"S664","DOI":"10.1093\/ofid\/ofac492.1357","article-title":"Tolerability and pharmacokinetics of oral epetraborole at the predicted therapeutic dosage for Mycobacterium avium complex (MAC) lung disease: a phase 1b dose-ranging and food effect study","volume":"9","author":"Eckburg","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"24","key":"10.1016\/j.ccm.2023.06.009_bib85","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1016\/j.bmc.2016.07.029","article-title":"Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic","volume":"24","author":"Tanaka","year":"2016","journal-title":"Bioorg Med Chem"},{"issue":"3","key":"10.1016\/j.ccm.2023.06.009_bib86","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01947-20","article-title":"In\u00a0Vitro susceptibility testing of omadacycline against nontuberculous mycobacteria","volume":"65","author":"Brown-Elliott","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.ccm.2023.06.009_bib87","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jac\/dkac068","article-title":"Omadacycline efficacy in the hollow fibre system model of pulmonary Mycobacterium avium complex and potency at clinically attainable doses","volume":"77","author":"Chapagain","year":"2022","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ccm.2023.06.009_bib88","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ijid.2022.06.061","article-title":"Omadacycline in first-line combination therapy for pulmonary Mycobacterium abscessus infection: a case series","volume":"122","author":"Duah","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"2","key":"10.1016\/j.ccm.2023.06.009_bib89","doi-asserted-by":"crossref","first-page":"ofab002","DOI":"10.1093\/ofid\/ofab002","article-title":"Preliminary, real-world, multicenter experience with omadacycline for Mycobacterium abscessus infections","volume":"8","author":"Morrisette","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ccm.2023.06.009_bib90","doi-asserted-by":"crossref","first-page":"e01703","DOI":"10.1016\/j.idcr.2023.e01703","article-title":"Omadacycline for the treatment of Mycobacterium abscessus infections: case series and review of the literature","volume":"31","author":"Siddiqa","year":"2023","journal-title":"IDCases"},{"issue":"4","key":"10.1016\/j.ccm.2023.06.009_bib91","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02469-20","article-title":"The benzimidazole SPR719 shows promising concentration-dependent activity and synergy against nontuberculous mycobacteria","volume":"65","author":"Pennings","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.ccm.2023.06.009_bib92","doi-asserted-by":"crossref","first-page":"e0120821","DOI":"10.1128\/AAC.01208-21","article-title":"First-in-human evaluation of the safety, tolerability, and pharmacokinetics of SPR720, a novel oral bacterial DNA gyrase (GyrB) inhibitor for mycobacterial infections","volume":"65","author":"Talley","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.ccm.2023.06.009_bib93","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4103\/ijmy.ijmy_73_18","article-title":"Antimycobacterial activity of veterinary antibiotics (Apramycin and Framycetin) against Mycobacterium abscessus: implication for patients with cystic fibrosis","volume":"7","author":"Moore","year":"2018","journal-title":"Int J Mycobacteriol"},{"issue":"1","key":"10.1016\/j.ccm.2023.06.009_bib94","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/cid\/ciac453","article-title":"Phage therapy of Mycobacterium infections: compassionate use of phages in 20 patients with drug-resistant mycobacterial disease","volume":"76","author":"Dedrick","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.ccm.2023.06.009_bib95","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1021\/acsinfecdis.0c00113","article-title":"Gallium porphyrin and gallium nitrate synergistically inhibit Mycobacterial species by targeting different aspects of iron\/heme metabolism","volume":"6","author":"Choi","year":"2020","journal-title":"ACS Infect Dis"},{"issue":"8","key":"10.1016\/j.ccm.2023.06.009_bib96","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1021\/acsinfecdis.0c00896","article-title":"Nanoparticulate beta-cyclodextrin with gallium tetraphenylporphyrin demonstrates in\u00a0vitro and in\u00a0vivo antimicrobial efficacy against Mycobacteroides abscessus and Mycobacterium avium","volume":"7","author":"Choi","year":"2021","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.ccm.2023.06.009_bib97","doi-asserted-by":"crossref","first-page":"128645","DOI":"10.1016\/j.bmcl.2022.128645","article-title":"Synthesis and in\u00a0vitro analysis of novel gallium tetrakis(4-methoxyphenyl)porphyrin and its long-acting nanoparticle as a potent antimycobacterial agent","volume":"62","author":"Choi","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"10.1016\/j.ccm.2023.06.009_bib98","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1152\/physrev.00034.2003","article-title":"Nitric oxide in health and disease of the respiratory system","volume":"84","author":"Ricciardolo","year":"2004","journal-title":"Physiol Rev"},{"issue":"9","key":"10.1016\/j.ccm.2023.06.009_bib99","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1128\/AAC.00347-07","article-title":"Innate protection of Mycobacterium smegmatis against the antimicrobial activity of nitric oxide is provided by mycothiol","volume":"51","author":"Miller","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.ccm.2023.06.009_bib100","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/INF.0000000000001780","article-title":"Compassionate nitric oxide adjuvant treatment of persistent Mycobacterium infection in cystic fibrosis patients","volume":"37","author":"Yaacoby-Bianu","year":"2018","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.ccm.2023.06.009_bib101","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jcf.2019.05.002","article-title":"Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection","volume":"19","author":"Bentur","year":"2020","journal-title":"J\u00a0Cyst Fibros"},{"key":"10.1016\/j.ccm.2023.06.009_bib102","doi-asserted-by":"crossref","first-page":"107069","DOI":"10.1016\/j.rmed.2022.107069","article-title":"Inhaled nitric oxide for adults with pulmonary non-tuberculous mycobacterial infection","volume":"206","author":"Flume","year":"2023","journal-title":"Respir Med"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523123000606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523123000606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:15:37Z","timestamp":1759454137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272523123000606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":102,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0272523123000606"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2023.06.009","relation":{},"ISSN":["0272-5231"],"issn-type":[{"value":"0272-5231","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Mycobacterium avium Complex Pulmonary Disease: When Should I Treat and What Therapy Should I Start?","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2023.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}